Photocure Norway

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

for further information on our commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com.

About Clinigen

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries and provides access in more than 130 countries every year. For more information on Clinigen, please visit http://www.clinigengroup.com.  

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: [e-mail]

Erik Dahl
CFO
Photocure ASA
Tel: [phone]
Email: [e-mail]

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: [phone]
Email: [e-mail]

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: [phone]
Email: [e-mail]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/photocure/r/photocure-establishes-named-patient-program-to-provide-access-to-hexvix-in-south-africa,c4043607

The following files are available for download:

https://mb.cision.com/Main/17498/4043607/3025337.pdf

Release

 

View original content:https://www.prnewswire.co.uk/news-releases/photocure-establishes-named-patient-program-to-provide-access-to-hexvix-in-south-africa-302260848.html